Skip to main content

Advertisement

SpringerLink
Log in

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The potential predictive value of tumor bulk, genetic, and immunological variants in patients with low-grade non-Hodgkin's lymphoma to respond to treatment with rituximab (RTX) monotherapy was evaluated. Thus, the value of assessing the effect of 18-fluoro-desoxy-d-glucose (FDG) uptake on PET scan, polymorphisms in Fc gamma receptor (FcγR) IIIa-158, FcγRIIa-131, and C1qA-276 genes in predicting the response to treatment were evaluated in 50 low-grade non-Hodgkin's lymphoma patients. The influence of RTX pharmacokinetics, plasma levels of the B cell-activating factor (BAFF), and human antichimeric antibodies was also investigated. The therapeutic response was evaluated 10 weeks after treatment using revised Cheson's criteria. Lower maximal standardized uptake values (SUVmax) at baseline were predictive of complete response. FcγRIIIa-158 polymorphism was also associated with complete response to RTX confirming previous findings, whereas polymorphisms in the FcγRIIa-131 and C1qA-276 genes were not. Lower blood levels of RTX were observed in males, but the effectiveness of RTX in males and females was the same. BAFF was not detectable in plasma before or after treatment, and no patients developed human antichimeric antibodies. Low-grade non-Hodgkin's lymphoma patients with a low SUVmax at baseline and an FcγRIIIa-158 V/V genotype generally had a complete response to RTX.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maloney DG, Grillo-López AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188–2195

    PubMed  CAS  Google Scholar 

  2. Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51

    Article  PubMed  CAS  Google Scholar 

  3. Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, Pers JO, Saraux A, Youinou P (2009) Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 76:458–463

    Article  PubMed  CAS  Google Scholar 

  4. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–535

    Article  PubMed  CAS  Google Scholar 

  5. Dall’Ozzo S, Tartas S, Paintaud G et al (2004) Rituximab-dependent cytotoxicity by NK cells: influence of FcγRIIIa polymorphism on the concentration–effect relationship. Cancer Res 64:4664–4669

    Article  PubMed  Google Scholar 

  6. Van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cell cytotoxicity. Clin Cancer Res 12:4027–4035

    Article  PubMed  Google Scholar 

  7. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant B cells. Cancer Immunol Immunother 48:673–683

    Article  PubMed  CAS  Google Scholar 

  8. Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in Fc-gamma receptor IIIa gene. Blood 99:754–758

    Article  PubMed  CAS  Google Scholar 

  9. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947

    Article  PubMed  CAS  Google Scholar 

  10. Racila E, Link BK, Weng W et al (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697–6703

    Article  PubMed  CAS  Google Scholar 

  11. Berinstein NL, Grillo-López AJ, White CA et al (1998) Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995–1001

    Article  PubMed  CAS  Google Scholar 

  12. Davis TA, Grillo-López AJ, White CA et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143

    PubMed  CAS  Google Scholar 

  13. Novak AJ, Grote DM, Stenson M et al (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin's lymphoma: correlation with disease activity and patient outcome. Blood 104:2247–2253

    Article  PubMed  CAS  Google Scholar 

  14. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465–475

    Article  PubMed  CAS  Google Scholar 

  15. Pers J, Devauchelle V, Daridon C et al (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 56:1464–1477

    Article  PubMed  Google Scholar 

  16. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Staging Classification. Cancer Res 31:1860–1861

    PubMed  CAS  Google Scholar 

  17. Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265

    Article  PubMed  Google Scholar 

  18. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  PubMed  Google Scholar 

  19. Cragg MS, Bayne MB, Tutt AL et al (2004) A new anti-Id antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104:2540–2542

    Article  PubMed  CAS  Google Scholar 

  20. Saito Y, Miyagawa Y, Onda K et al (2008) BAFF inhibits CD20-mediated and BCR-mediated apoptosis in human B cells. Immunology 125:570–590

    Article  PubMed  CAS  Google Scholar 

  21. Le Pottier L, Bendaoud B, Renaudineau Y et al (2009) New ELISA for BAFF. Clin Chem 55:1843–1851

    Article  PubMed  Google Scholar 

  22. Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15:42–52

    Article  PubMed  CAS  Google Scholar 

  23. Teeling JL, French RR, Cragg MS et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphoma. Blood 104:1793–1800

    Article  PubMed  CAS  Google Scholar 

  24. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91:522–529

    PubMed  Google Scholar 

  25. Le Dortz L, De Guibert S, Bayat S et al (2010) Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307–2314

    Article  PubMed  Google Scholar 

  26. Cazaentre T, Morschhauser F, Bermandel M et al (2010) Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:494–504

    Article  PubMed  CAS  Google Scholar 

  27. Hatjiharissi E, Xu L, Santos DD et al (2007) Increased NK cell expression of CD16, augmented binding and ADCC activity of rituximab among individuals expressing the FcγRIIIa-158V/V and V/F polymorphism. Blood 110:2561–2564

    Article  PubMed  CAS  Google Scholar 

  28. Wu J, Edberg JC, Redecha PB et al (1997) A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059–1070

    Article  PubMed  CAS  Google Scholar 

  29. Anolik JH, Campbell D, Felgar RE et al (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459

    Article  PubMed  CAS  Google Scholar 

  30. Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B (2007) FcγRIIIa and FcγRIIa polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92:998–999

    Article  PubMed  Google Scholar 

  31. Carlotti E, Palumbo GA, Oldani E et al (2007) FcγRIIIa and FcγRIIa polymorphisms do not predict clinical outcome of follicular NHL patients treated with sequential CHOP and rituximab. Haematologica 92:1127–1130

    Article  PubMed  CAS  Google Scholar 

  32. Weng WK, Levy R (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 50:723–727

    Article  PubMed  CAS  Google Scholar 

  33. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms in White patients, and for an FcγRIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26:5489–5491

    Article  PubMed  Google Scholar 

  34. Di Gaetano N, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581–1587

    PubMed  Google Scholar 

  35. Nielsen CH, Fischer EM, Leslie RG (2000) The role of complement in the acquired immune response. Immunology 100:4–12

    Article  PubMed  CAS  Google Scholar 

  36. Uchida J, Hamaguchi Y, Oliver JA et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659–1669

    Article  PubMed  CAS  Google Scholar 

  37. Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830

    Article  PubMed  CAS  Google Scholar 

  38. Novak AJ, Slager SL, Fredericksen ZS et al (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69:4217–4224

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Many thanks go to Geneviève Michel and Simone Forest for their assistance with the typing of this manuscript. The expert editorial help of Prof. Rizgar A Mageed (London, UK) is also appreciated.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. EA2216 “Immunology and Pathology” and IFR146 “ScInBios”, Université Européenne de Bretagne, Brest, France

    Divi Cornec, Pascal Hutin, Jacques-Olivier Pers, Christophe Jamin, Boutahar Bendaoud, Christian Berthou, Yves Renaudineau & Pierre Youinou

  2. Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France

    Divi Cornec, Jacques-Olivier Pers, Christophe Jamin, Boutahar Bendaoud, Yves Renaudineau & Pierre Youinou

  3. Department of Clinical Oncology, Brest University Medical School Hospital, Brest, France

    Adrian Tempescul & Christian Berthou

  4. Unit of Nuclear Medicine, Brest University Medical School Hospital, Brest, France

    Solène Querellou

Authors
  1. Divi Cornec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian Tempescul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Solène Querellou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pascal Hutin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacques-Olivier Pers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christophe Jamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Boutahar Bendaoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Berthou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yves Renaudineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre Youinou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Youinou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cornec, D., Tempescul, A., Querellou, S. et al. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol 91, 715–721 (2012). https://doi.org/10.1007/s00277-011-1369-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-011-1369-y

Keywords

Search

Navigation